TABLE 2.

Characteristics and pregnancy outcomes of patients with pregnancy‐associated sarcomas (n = 13)

Patient No.	Histology	Type of pregnancy	Systemic therapy during pregnancy	Gestational week systemic therapy started (weeks)	Pregnancy complications	Live fetal birth?	Gestational age at birth or fetal demise (weeks)
1	Malignant peripheral nerve sheath tumor	Natural	Epirubicin/Ifosfamide	24	Fetal growth restriction	Yes	26
2	Osteosarcoma	Natural	Doxorubicin/Ifosfamide	22	Fetal growth restriction, anhydramnios, maternal hemoperitoneum	Yes	27
3	Synovial sarcoma	In vitro fertilization	Doxorubicin/Ifosfamide	16	Fetal growth restriction, anhydramnios, intrauterine fetal demise	No	20
4	Osteosarcoma	Natural	Doxorubicin/Cisplatin	21	None	Yes	36
5	Ewing sarcoma	Natural	Vincristine, Doxorubicin, Cyclophosphamide alternating with Ifosfamide and Etoposide	16	Fetal growth restriction, fetal demise found at time of induction for abnormal umbilical artery Doppler study	No	24
6	Myxofibrosarcoma	Natural	Doxorubicin/Ifosfamide	22	Reduced fetal movements, abnormal intrauterine fetal heart rates	Yes	26
7	High‐grade spindle cell sarcoma	Natural	Doxorubicin/Ifosfamide	13	Intrauterine stillbirth	No	16
8	Osteosarcoma	Natural	Doxorubicin/Cisplatin	23	None	Yes	34
9	Desmoid	Natural	Doxorubicin	16	Fetal growth restriction	Yes	33
10	Unclassified small cell malignancy	Natural	Doxorubicin/Cyclophosphamide ‐>Doxorubicin/Ifosfamide	18	Fetal growth restriction, asymmetric growth restriction	Yes	32
11	High‐grade spindle cell sarcoma	Natural	Doxorubicin/Ifosfamide	27	Oligohydramnios	Yes	30
12	High grade spindle cell sarcoma	Intrauterine insemination	Doxorubicin/Ifosfamide	17	Fetal demise	No	23
13	Embryonal rhabdomyosarcoma	Natural	Vincristine/Doxorubicin/Cyclophosphamide	19	None	Yes	34